Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics has reported total revenues of $23.19m for the second quarter ended 30 June 2011, compared to $3.21m for the same period in 2010.
Subscribe to our email newsletter
Halozyme’s net income was $3.12m, or $0.03 per diluted share, compared to net loss of $12.15m, or $0.13 loss per diluted share, for the same period in 2010.
The company’s operating income for the second quarter of 2011 was $3.01m, compared to operating loss of $12.15m for the same period in 2010.
For the six months ended 30 June 2011, the company reported total revenues of $30.73m, compared to $6.66m for the same period in 2010.
The company has reported net loss of $6.52m or 0.06 loss per diluted share for the six months ended 30 June 2011, as compared to $23.94m or $0.26 loss per diluted share for the same period in 2010.
Halozyme’s loss from operations was $6.56m for the six months of 2011, compared to $23.94m for the same period in 2010.
Halozyme president and CEO Gregory Frost said the complete dataset from their PH20-Aspart studies in patients with type 1 diabetes was encouraging, revealing decreased variability of insulin absorption and reduced post-glycemic excursions via pump infusions over three days of infusion set life.